{"id":"W4403303732","doi":"10.1128/spectrum.01474-24","title":"<i>In vitro</i> activity assessment of cefiderocol against Enterobacterales, <i>Pseudomonas aeruginosa,</i> and <i>Acinetobacter</i> spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals","year":2024,"lang":"en","type":"article","venue":"Microbiology Spectrum","topic":"Antibiotic Resistance in Bacteria","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Genentech; U.S. Food and Drug Administration; Astellas Pharma; Basilea Pharmaceutica; Ohio State University; Nabriva Therapeutics; Pfizer; Entasis Therapeutics; Wockhardt; Mundipharma International; Zoetis; Menarini Group; McGill University; Roche; Cidara Therapeutics; Medpace; Carnegie Mellon University; TenNor Therapeutics; Harvard University; National Institutes of Health; Meiji Seika Pharma; Shionogi; National Cancer Institute; Gilead Sciences; Dr. Falk Pharma","keywords":"Microbiology; Pseudomonas aeruginosa; Acinetobacter baumannii; Cephalosporin; Biology; Acinetobacter calcoaceticus; Antimicrobial; Ceftazidime/avibactam; Carbapenem; Acinetobacter; Imipenem; Klebsiella pneumoniae; Meropenem; Escherichia coli; Ceftazidime; Antibiotic resistance; Antibiotics; Bacteria; Gene; Genetics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004674771,0.0004692298,0.0003046351,0.0004449304,0.0001613415,0.0004474282,0.0001924162,0.0002434152,0.0009044984],"category_scores_gemma":[0.0006099092,0.0001155545,0.0003767659,0.0004571821,0.0001069058,0.0002464461,0.0002402893,0.0002594065,0.0002995621],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002443632,"about_ca_system_score_gemma":0.0002385751,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002449938,"about_ca_topic_score_gemma":0.002993142,"domain_scores_codex":[0.9994506,0.0001239273,0.00009967262,0.00009488433,0.0001545327,0.00007626416],"domain_scores_gemma":[0.9994493,0.00008333589,0.000132127,0.0000286175,0.0002549025,0.00005171957],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001785305,0.001014987,0.1763634,0.0005015894,0.0002084008,0.0002348975,0.0002590658,0.0008886389,0.7978478,0.00006192306,0.0008669317,0.0199671],"study_design_scores_gemma":[0.00005641171,0.01020197,0.4111945,0.0000943233,0.0002207306,0.001234821,0.0005318203,0.001128587,0.5692165,0.00002782379,0.006057813,0.00003472625],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959041,0.0008846314,0.0002259274,0.00003027188,0.00001846437,0.00003438957,0.001790661,0.000008430266,0.001103044],"genre_scores_gemma":[0.9880223,0.0009259506,0.001193635,0.00008041984,0.00002222339,0.00003175351,0.008654803,0.000005693244,0.001063231],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002449938,"threshold_uncertainty_score":0.004871368,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005618348930727269,"score_gpt":0.2396254263705721,"score_spread":0.2340070774398448,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}